The sale of iMAX Diagnostic Imaging for Hovione marks the end of a 24 years history of reliable and uninterrupted supply of iopamidol and iohexol to the generic industry globally.
Hovione entered the generic contrast media business in 1993 and in 2007 moved most of its manufacture to the iMAX factory in China because its capacity in Europe was no longer able to meet clients’ demand.
Continuing to show a steady profitable growth, for most of that period the iMAX factory output represented the largest tonnage of Hovione’s product portfolio. For 20 years formulations containing Hovione’s contrast media have been supplied to the growing markets of Asia and have included Japan’s best selling generic medicine.
Faced with considerable opportunities in both the contrast agents business and all its other segments, Hovione decided to focus on its CDMO business, on its off-patent business supplying highly specialised APIs and to exit the large volume business of contrast media. The significant expansion plans that Hovione embarked upon since 2016 requires all of its attention.
"Getting into iopamidol and iohexol was a decision we took in 1993. Today Hovione’s strategy focuses on difficult to make and difficult to formulate products, supplied to demanding markets, serving innovative clients. Our contrast media business is growing and has many loyal clients that demand high quality, but it increasingly does not seem a good fit with the rest of our activities."
"The opportunity to sell iMAX with its manufacturing business of APIs and formulated product to a market leader makes sure this business can continue to develop even better. We are convinced that the buyer will be good owner and employer, and will continue supplying reliably the great clients that have supported iMAX’s growth." said Guy Villax, CEO of Hovione.
